Compare Novavax Inc (NVAX) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Novavax Inc trades at $12.16 (market cap $1.82B), while iShares 0 3 Month Treasury Bond ETF trades at $100.51 (market cap $114.40B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 62.9× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and iShares 0 3 Month Treasury Bond ETF for 50 Days on average.
| NVAX | SGOV | |
|---|---|---|
Market Cap | $1.82B | $114.40B |
Volume | 6,198,505 | 18,879,081 |
Sector | Health | Fixed Income |
52-Week High | $12.56 | $100.72 |
52-Week Low | $6.22 | $100.28 |
Typical Hold Time | 59 Days | 50 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
SGOV trades at $100.51 with minimal daily movement (+0.04%), reflecting its stable Treasury bond ETF nature. Technical indicators show bearish momentum with oversold RSI readings, while fundamental data remains limited for this short-term Treasury fund. Recent institutional selling by Envestnet Asset Management indicates some professional caution, though the fund continues regular dividend distributions.
The outlook remains stable given SGOV's short-term Treasury focus, though rising bond yields present both opportunity and risk. Investors benefit from monthly dividends but face interest rate sensitivity. Current technical weakness suggests potential near-term pressure despite the fund's defensive characteristics in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
